A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer
A Phase 2, Open-label Study of IMC-1121B in Combination With Paclitaxel and Carboplatin as First-line Therapy in Patients With Stage IIIB/IV Non-small Cell Lung Cancer
調査の概要
詳細な説明
Non-small cell lung cancer (NSCLC) accounts for 75-80% of all lung cancers. The advanced stages are associated with poor survival rates, a median survival rate of approximately 3.9 months if left untreated.
Angiogenesis is a process for wound healing and restoring blood flow to tissues after injury. It is the physiological process involving the growth of new blood vessels from pre-existing vessels. Angiogenesis may be promoted by growth factors and in diseases such as cancer, where growth factors are over expressed, the body loses the ability to maintain a balanced angiogenesis. This may embellish the existing supplies of blood; potentially increasing the delivery of oxygen and nutrients supplies for cancer growth and survival.
Ramucirumab is an angiogenesis inhibitor; and is believed to block the promotion of the growth factor to form new blood vessels, thus reducing the blood supply to the cancer cells.
研究の種類
入学 (実際)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
California
-
Beverly Hills、California、アメリカ、90211
- ImClone Investigational Site
-
San Francisco、California、アメリカ、94143
- ImClone Investigational Site
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045
- ImClone Investigational Site
-
-
New York
-
Bronx、New York、アメリカ、10467
- ImClone Investigational Site
-
New York、New York、アメリカ、10016
- ImClone Investigational Site
-
-
Texas
-
San Antonio、Texas、アメリカ、78229
- ImClone Investigational Site
-
-
Washington
-
Seattle、Washington、アメリカ、98104
- ImClone Investigational Site
-
-
-
-
-
Cambridge、イギリス
- ImClone Investigational Site
-
London、イギリス
- ImClone Investigational Site
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Histologically or cytologically confirmed NSCLC
- Advanced NSCLC
- Measurable disease (as defined by Response Evaluation Criteria in Solid Tumors [RECIST 1.0])
- Eastern Cooperative Oncology Group (ECOG) Performance Status is ≤ 1
- Age ≥ 18 years
- Adequate hematologic function = an absolute neutrophil count (ANC) ≥ 1500/μL, hemoglobin ≥ 9 g/dL, and a platelet count ≥ 100,000/microliter (μL)
- Adequate hepatic function = a total bilirubin ≤ 1.5 mg/dL transaminases and alkaline phosphatase ≤ 5 x the upper limit of normal (ULN)
- Adequate renal function serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance (CrCl) > 60 mL/minute, and urine dipstick for protein < 1+ (ie, either 0 or trace)
- Adequate coagulation function, INR ≤ 1.5 and a partial thromboplastin time (PTT) ≤ 5 seconds above ULN
- Adequate contraception
- Signed informed consent
Exclusion Criteria:
- Untreated CNS metastases
- Prior bevacizumab therapy
- Radiologically documented evidence of major blood vessel invasion or encasement by cancer
- Prior systemic chemotherapy for Stage IIIB/IV NSCLC
- Prior systemic chemotherapy or radiation therapy for Stage I-IIIA NSCLC < 1 year prior
- Any concurrent malignancy other than basal cell skin cancer, or carcinoma in situ of the cervix
- Concurrent treatment with other anticancer therapy, including other chemotherapy, immunotherapy, hormonal therapy, radiotherapy, chemoembolization, or targeted therapy
- Ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Uncontrolled thrombotic or hemorrhagic disorders
- Poorly-controlled hypertension
- Chronic daily treatment with aspirin (> 325 mg/day) or other known inhibitors of platelet function
- History of gross hemoptysis (defined as bright red blood or ≥ 1/2 teaspoon)
- Serious non-healing wound, ulcer, or bone fracture
- Undergone major surgery or subcutaneous venous access device placement. Post-operative bleeding complications or wound complications from a surgical procedures performed in the last 2 months
- Elective or a planned major surgery to be performed during the course of the trial
- Peripheral neuropathy ≥ Grade 2 (National Cancer Institute Common Toxicity Criteria for Adverse Events, Version 3.0 [NCI-CTCAE v 3.0])
- If female, is pregnant or lactating
- Radiographic evidence of intratumor cavitation
- Grade 3-4 gastrointestinal bleeding within 3 months prior to study entry
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：なし
- 介入モデル：単一グループの割り当て
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：ramucirumab + paclitaxel + carboplatin
Participants will receive ramucirumab in combination with paclitaxel and carboplatin until disease progression, the development of an unacceptable toxicity, or other withdrawal criteria, for up to six cycles (3 weeks per cycle). In the absence of any withdrawal criteria, participants will continue to receive ramucirumab monotherapy every 3 weeks, provided there is ongoing evidence of benefit upon review every 6 weeks. |
10 milligrams per kilogram (mg/kg), intravenous (IV) infusion, on Day 1 of each 21-day cycle.
他の名前：
200 milligrams per meter squared (mg/m^2), administered intravenously (IV) following the ramucirumab infusion, on day 1 of each 21-day cycle, for up to six cycles.
Administered after paclitaxel, as an intravenous infusion (IV), over 30 minutes on day 1 of each 21-day cycle, for up to six cycles.
The dose to be administered is calculated based on the participant's actual body weight at time of treatment and the area under the curve (AUC) dosing.
The target AUC for carboplatin treatment is AUC=6.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of Participants Who Are Progression-free (PFS) at 6 Months
時間枠：6 months
|
Data presented are the percentage of participants without disease progression or death at 6 months.
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0).
Progressive disease was defined as having at least a 20% increase in sum of longest diameter of target lesions or the appearance of one or more new lesions and/or unequivocal progression of existing nontarget lesions.
|
6 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Summary of Participants Reporting Adverse Events
時間枠：Baseline up to 32.5 months
|
Data presented are the number of participants who experienced ramucirumab related treatment-emergent adverse events (TEAE), treatment related serious adverse events (SAE), or any Grade 3 or higher TEAE; any TEAE leading to discontinuation of ramucirumab treatment, and any TEAE leading to dose modification ramucirumab.
A summary of SAEs and other nonserious AEs, regardless of causality, is located in the Reported Adverse Event section.
|
Baseline up to 32.5 months
|
|
Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate ([ORR])
時間枠：First dose to measured progressive disease or death due to any cause up to 32.5 months
|
Objective response is Complete Response (CR) + Partial Response (PR), as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST 1.0) guidelines.
CR is a disappearance of all target and non-target lesions; PR is at least a 30% decrease in the sum of the longest diameter of target lesions without new lesions and progression of non-target lesions.
Objective response rate is calculated as a total number of participants with CR or PR divided by the total number of participants with measurable disease, multiplied by 100.
|
First dose to measured progressive disease or death due to any cause up to 32.5 months
|
|
Duration of Response
時間枠：First dose up to 32.5 months
|
The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression, initiation of additional antitumor therapy is first reported, or death as a result of any cause.
CR was defined as the disappearance of all target lesions.
PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions.
|
First dose up to 32.5 months
|
|
Overall Survival (OS) at 1 Year
時間枠：First dose to 1 year
|
Data presented are the percentage of participants surviving at least 12 months after first dose of study medication.
|
First dose to 1 year
|
|
Progression-free Survival (PFS)
時間枠：First dose to measured progressive disease or death due to any cause, up to 32.5 months
|
Defined as the time from date of first dose of study medication to the first documented disease progression as defined by Response Evaluation Criteria In Solid Tumors (RECIST 1.0), initiation of additional antitumor therapy was first reported or death due to any cause. Participants who did not progress, who discontinued treatment for toxicity or a reason other than documented progression, or who were lost to follow-up before documented progression or death were censored at date of last tumor assessment. Participants who started new therapeutic anticancer treatment prior to documented progression or death were censored at date of last tumor assessment prior to new therapeutic anticancer therapy. |
First dose to measured progressive disease or death due to any cause, up to 32.5 months
|
|
Overall Survival (OS)
時間枠：First dose to death due to any cause, up to 32.5 months
|
Overall survival is defined as the time from the first dose of study medication to the date of death from any cause.
Participants who were alive at the end of the follow-up period or lost to follow-up were censored on the last date the patient was known to be alive.
|
First dose to death due to any cause, up to 32.5 months
|
|
Serum Anti-Ramucirumab Antibody Assessment
時間枠：Week 15 (Cycle 5)
|
The number of participants who developed treatment emergent antibody responses to ramucirumab after baseline.
|
Week 15 (Cycle 5)
|
|
Maximum Concentration of Ramucirumab (Cmax)
時間枠：Week 18 (Cycle 6), at 1-Hour Post End of Infusion
|
Week 18 (Cycle 6), at 1-Hour Post End of Infusion
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 13914
- 2007-006715-22 (EudraCT番号)
- CP12-0708 (その他の識別子：ImClone Systems)
- I4T-IE-JVBJ (その他の識別子：Eli Lilly and Company)
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。